Adoptive Immunotherapy

Khatri et al. demonstrated the striking temporal relationship between the endogenous expansion of a TCR Vfi-restricted, CD3+CD8+ population of MHC class I-restricted CTL and the regression of a monoclonal PTLD in a HSCT recipient. Unfortunately, the delay in recovery of such immune surveillance against transformed EBV-positive B cells results in the development of potentially fatal PTLD. T-cell immunotherapy has been reported to be efficacious in the management of PTLD in this setting.39 O'Reilly et al. reported on 18 HSCT patients with EBV-PTLD who were treated with nonspecific donor lymphocyte infusions (DLI): 16 of 18 patients experienced eradication of PTLD. However, only 10 survived in sustained CR and 3 patients died of GVHD, a major side effect of DLI.50 Attempts have been made to improve the efficacy and reduce the risk of GVHD by administering EBV-spe-cific CTLs.51 Rooney et al. detailed the outcome of 39 recipients of matched unrelated donor/partially mismatched related donor transplants who received prophylactic EBV-specific CTLs (EBVs-CTL). None of the treated HSCT recipients developed PTLD, whereas 7 of 61 controls not receiving such therapy developed PTLD.52

In the SOT setting, adoptive immunotherapy has also been evaluated on a limited basis. Nalesnick et al. reported the experience of seven SOT recipients with PTLD; peripheral blood mononuclear cells harvested from the patients were cultured with interleukin-2 (IL-2). The infusion of these lymphokine-activated killer cells into the four patients with EBV-positive tumors resulted in sustained involution of their tumors. Unfortunately, two patients suffered organ rejection.53 Haque et al. reported their experience with three SOT patients whose EBV-specific cells lines were cultured from autologous T cells collected prior to transplant; the prophylactic infusion of these cells after transplant resulted in the suppression of circulating EBV-DNA levels to below pretansplant levels. Interestingly, the EBV-specific CTLs were measurable in the patients' blood for 3 months posttransplant.54 Finally, a phase 1/2 trial with eight SOT patients who had progressive PTLD unresponsive to conventional treatment were given infusions of partly HLA-matched allogeneic EBV-specific CTLs from a frozen bank of CTLs derived from healthy blood donors. Three of the five patients who completed treatment achieved a complete remission, and the EBV load in their peripheral blood fell to undetectable levels in all patients who responded to treatment; no GVHD developed and graft function improved in three cases.55 It was noted that tumor responses were mainly seen in those with early, localized, polyclonal disease.

EBVs-CTL therapy may not find widespread use for several reasons: it requires 2-3 weeks to generate such cells, the technology for larger scale expansion of EBV-CTLs is expensive, such technology is not available in every transplant center, and this approach is not effective in patients who develop EBV deletion mutants.11

How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book

Post a comment